Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer

M. T. Schweizer, J. Lin, A. Blackford, A. Bardia, S. King, A. J. Armstrong, Michelle Rudek-Renaut, S Yegnasubramanian, Michael A Carducci

Research output: Contribution to journalArticle

Abstract

Background:Preclinical drug screens identified disulfiram as a potent in vitro inhibitor of prostate cancer (PCa) cell growth. Although many mechanisms for its anticancer activity have been proposed, tumor suppressor gene re-expression through promoter demethylation emerged as one of the more plausible.Methods:We conducted an open-label, dose escalation trial of disulfiram in men with non-metastatic recurrent PCa after local therapy. Dose escalation occurred if a demethylating 'response' (that is, ≥10% decrease in peripheral blood mononuclear cell (PBMC) global 5-methyl cytosine (5 me C) content) was observed in

Original languageEnglish (US)
Pages (from-to)357-361
Number of pages5
JournalProstate Cancer and Prostatic Diseases
Volume16
Issue number4
DOIs
StatePublished - Dec 2013

Fingerprint

Disulfiram
Prostatic Neoplasms
Cytosine
Tumor Suppressor Genes
Blood Cells
Gene Expression
Growth
Pharmaceutical Preparations
Therapeutics
In Vitro Techniques

Keywords

  • Demethylation
  • Disulfiram
  • Epigenetics
  • Hypomethylation

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Cite this

Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer. / Schweizer, M. T.; Lin, J.; Blackford, A.; Bardia, A.; King, S.; Armstrong, A. J.; Rudek-Renaut, Michelle; Yegnasubramanian, S; Carducci, Michael A.

In: Prostate Cancer and Prostatic Diseases, Vol. 16, No. 4, 12.2013, p. 357-361.

Research output: Contribution to journalArticle

Schweizer, M. T. ; Lin, J. ; Blackford, A. ; Bardia, A. ; King, S. ; Armstrong, A. J. ; Rudek-Renaut, Michelle ; Yegnasubramanian, S ; Carducci, Michael A. / Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer. In: Prostate Cancer and Prostatic Diseases. 2013 ; Vol. 16, No. 4. pp. 357-361.
@article{387c58813ba541f69618ce9742fefcfb,
title = "Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer",
abstract = "Background:Preclinical drug screens identified disulfiram as a potent in vitro inhibitor of prostate cancer (PCa) cell growth. Although many mechanisms for its anticancer activity have been proposed, tumor suppressor gene re-expression through promoter demethylation emerged as one of the more plausible.Methods:We conducted an open-label, dose escalation trial of disulfiram in men with non-metastatic recurrent PCa after local therapy. Dose escalation occurred if a demethylating 'response' (that is, ≥10{\%} decrease in peripheral blood mononuclear cell (PBMC) global 5-methyl cytosine (5 me C) content) was observed in",
keywords = "Demethylation, Disulfiram, Epigenetics, Hypomethylation",
author = "Schweizer, {M. T.} and J. Lin and A. Blackford and A. Bardia and S. King and Armstrong, {A. J.} and Michelle Rudek-Renaut and S Yegnasubramanian and Carducci, {Michael A}",
year = "2013",
month = "12",
doi = "10.1038/pcan.2013.28",
language = "English (US)",
volume = "16",
pages = "357--361",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer

AU - Schweizer, M. T.

AU - Lin, J.

AU - Blackford, A.

AU - Bardia, A.

AU - King, S.

AU - Armstrong, A. J.

AU - Rudek-Renaut, Michelle

AU - Yegnasubramanian, S

AU - Carducci, Michael A

PY - 2013/12

Y1 - 2013/12

N2 - Background:Preclinical drug screens identified disulfiram as a potent in vitro inhibitor of prostate cancer (PCa) cell growth. Although many mechanisms for its anticancer activity have been proposed, tumor suppressor gene re-expression through promoter demethylation emerged as one of the more plausible.Methods:We conducted an open-label, dose escalation trial of disulfiram in men with non-metastatic recurrent PCa after local therapy. Dose escalation occurred if a demethylating 'response' (that is, ≥10% decrease in peripheral blood mononuclear cell (PBMC) global 5-methyl cytosine (5 me C) content) was observed in

AB - Background:Preclinical drug screens identified disulfiram as a potent in vitro inhibitor of prostate cancer (PCa) cell growth. Although many mechanisms for its anticancer activity have been proposed, tumor suppressor gene re-expression through promoter demethylation emerged as one of the more plausible.Methods:We conducted an open-label, dose escalation trial of disulfiram in men with non-metastatic recurrent PCa after local therapy. Dose escalation occurred if a demethylating 'response' (that is, ≥10% decrease in peripheral blood mononuclear cell (PBMC) global 5-methyl cytosine (5 me C) content) was observed in

KW - Demethylation

KW - Disulfiram

KW - Epigenetics

KW - Hypomethylation

UR - http://www.scopus.com/inward/record.url?scp=84887615265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887615265&partnerID=8YFLogxK

U2 - 10.1038/pcan.2013.28

DO - 10.1038/pcan.2013.28

M3 - Article

C2 - 23958896

AN - SCOPUS:84887615265

VL - 16

SP - 357

EP - 361

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 4

ER -